Experimed

SUBMITINFORMATION
EnglishTürkçe

Research Article


DOI :10.26650/experimed.1378000   IUP :10.26650/experimed.1378000    Full Text (PDF)

A Clinical Sulfonamide Derivative Inhibits B-Raf Protein in Colorectal Cancer and Melanoma Cells. Is It a New Target for Cancer?

Emine Terzi, Beyza Ecem Öz Bedir

Objective: Colorectal cancer (CRC) is a type of cancer spreading quickly around the world. Melanoma is an aggressive and lethal form of skin cancer. One of the striking biomarkers in cancer is carbonic anhydrase (CA)-IX, which catalyzes the hydration of carbon dioxide (CO2). CA inhibitors are being used clinically and studied extensively in clinical research. This study aimed to examine the CA inhibitor acetazolamide (AZA) in terms of the B-Raf protein in colorectal cancer and the melanoma cell line.

Materials and Methods: HT29 human colorectal cancer cells and A375 human melanoma cells were cultured. The appropriate dose of AZA on the cells was determined by the WST-1 test. The enzyme-linked immunosorbent assay (ELISA) was used to determine the effect of AZA on the B-Raf protein in HT29 and A375 cells.

Results: HT29 and A375 cell lines treated with AZA showed a dramatic decrease in CA-IX levels (p<0.05). In addition, AZA significantly reduced B-Raf protein levels in the HT29 and A375 cell lines (p<0.05, for both).

Conclusion: This study revealed AZA, a CA inhibitor, to be effective in CRC and melanoma. In future studies, combining the effects of AZA and B-Raf inhibitors may present an alternative approach in cancer treatment.

Keywords: Acetazolamide, B-Raf, carbonic anhydrase-IX, colorectal cancer, melanoma

PDF View

References

  • Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev 2021; 35(11-12):787-820. google scholar
  • Haraldsdottir S, Einarsdottir HM, Smaradottir A, Gunnlaugsson A, Halfdanarson TR. Krabbamein ^ ristli og enda^armi [Colorectal cancer - review]. Laeknabladid 2014; 100(2): 75-82. google scholar
  • Villani A, Scalvenzi M, Micali G, Lacarrubba F, Fornaro L, Martora F, et.al. Management of advanced invasive melanoma: New strategies. Adv Ther 2023; 40(8): 3381-94. google scholar
  • Takacova M, Holotnakova T, Barathova M, Pastorekova S, Kopacek J, Pastorek J. Src induces expression of carbonic anhydrase IX via hypoxia-inducible factor 1. Oncol Rep 2010; 23(3): 869-74. google scholar
  • Kumar S, Rulhania S, Jaswal S, Monga V. Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors. Eur J Med Chem 2021; 209: 112923. google scholar
  • Pastorek J, Pastorekova S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Semin Cancer Biol 2015; 31: 52-64. google scholar
  • Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev 2019; 38(1-2): 65-77. google scholar
  • Pastorekova S, Kopacek J, Pastorek J. Carbonic anhydrase inhibitors and the management of cancer. Curr Top Med Chem 2007; 7(9): 865-78. google scholar
  • Ward C, Meehan J, Gray M, Kunkler IH, Langdon SP, Argyle DJ. Carbonic anhydrase IX (CAIX), cancer, and radiation responsiveness. Metabolites 2018; 8(1): 13. google scholar
  • Lake D, Correa SA, Müller J. Negative feedback regulation of the ERK1/2 MAPK pathway. Cell Mol Life Sci 2016; 73(23): 4397-413. google scholar
  • Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26(22): 3291-310. google scholar
  • Low HB, Zhang Y. Regulatory roles of MAPK phosphatases in cancer. Immune Netw 2016; 16(2): 85-98. google scholar
  • Pakneshan S, Salajegheh A, Smith RA, Lam AK. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013; 45(4): 346-56. google scholar
  • Passardi A, Scarpi E, Ulivi P. Molecular and translational research on colorectal cancer. Int J Mol Sci 2020; 21(11): 4105. google scholar
  • Mishra H, Mishra PK, Ekielski A, Jaggi M, Iqbal Z, Talegaonkar S. Melanoma treatment: from conventional to nanotechnology. J Cancer Res Clin Oncol 2018; 144(12): 2283-302. google scholar
  • Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond. J Invest Dermatol 2021; 141(1): 23-31. google scholar
  • Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther 2019; 20(11): 1366-79. google scholar
  • Lopes J, Rodrigues CMP, Gaspar MM, Reis CP. Melanoma management: from epidemiology to treatment and latest advances. Cancers (Basel) 2022; 14(19): 4652 google scholar
  • Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet 2019; 394(10207): 1467-80. google scholar
  • Tabana YM, Dahham SS, Shah AM, Majid A. Major signaling pathways of colorectal carcinogenesis. Recent Adv Colon Cancer 2016; 1: 1–2. google scholar
  • Previs RA, Coleman RL, Harris AL, Sood AK. Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res 2015; 21(5): 955-61. google scholar
  • Li L, Zhao GD, Shi Z, Qi LL, Zhou LY, Fu ZX. The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol Lett 2016; 12(5): 3045-50. google scholar
  • Carr S, Smith C, Wernberg J. Epidemiology and risk factors of melanoma. Surg Clin North Am 2020; 100(1): 1-12. google scholar
  • Nicholas S, Mathios D, Jackson C, Lim M. Metastatic melanoma to the brain: surgery and radiation is still the standard of care. Curr Treat Options Oncol 2013; 14(2): 264-79. google scholar
  • Garbe C, Eigentler TK. Vemurafenib. Recent Results Cancer Res 2018; 211: 77-89. google scholar
  • Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat 2018; 28(10): 709-12. google scholar
  • Mokhtari RB, Kumar S, Islam SS, Yazdanpanah M, Adeli K, Cutz E, et. al. Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines. BMC Cancer 2013;13:378. google scholar
  • Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et.al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008; 105(8):3041-6. google scholar
  • Bellón T, Lerma V, González-Valle O, González Herrada C, de Abajo FJ. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds. Br J Dermatol 2016; 174(3): 621-4. google scholar
  • Ali EMH, Abdel-Maksoud MS, Ammar UM, Mersal KI, Ho Yoo K, Jooryeong P, et.al. Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAFV600E inhibitors. Bioorg Chem 2021; 106:104508. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Terzi, E., & Öz Bedir, B.E. (2024). A Clinical Sulfonamide Derivative Inhibits B-Raf Protein in Colorectal Cancer and Melanoma Cells. Is It a New Target for Cancer?. Experimed, 14(1), 7-12. https://doi.org/10.26650/experimed.1378000


AMA

Terzi E, Öz Bedir B E. A Clinical Sulfonamide Derivative Inhibits B-Raf Protein in Colorectal Cancer and Melanoma Cells. Is It a New Target for Cancer?. Experimed. 2024;14(1):7-12. https://doi.org/10.26650/experimed.1378000


ABNT

Terzi, E.; Öz Bedir, B.E. A Clinical Sulfonamide Derivative Inhibits B-Raf Protein in Colorectal Cancer and Melanoma Cells. Is It a New Target for Cancer?. Experimed, [Publisher Location], v. 14, n. 1, p. 7-12, 2024.


Chicago: Author-Date Style

Terzi, Emine, and Beyza Ecem Öz Bedir. 2024. “A Clinical Sulfonamide Derivative Inhibits B-Raf Protein in Colorectal Cancer and Melanoma Cells. Is It a New Target for Cancer?.” Experimed 14, no. 1: 7-12. https://doi.org/10.26650/experimed.1378000


Chicago: Humanities Style

Terzi, Emine, and Beyza Ecem Öz Bedir. “A Clinical Sulfonamide Derivative Inhibits B-Raf Protein in Colorectal Cancer and Melanoma Cells. Is It a New Target for Cancer?.” Experimed 14, no. 1 (May. 2024): 7-12. https://doi.org/10.26650/experimed.1378000


Harvard: Australian Style

Terzi, E & Öz Bedir, BE 2024, 'A Clinical Sulfonamide Derivative Inhibits B-Raf Protein in Colorectal Cancer and Melanoma Cells. Is It a New Target for Cancer?', Experimed, vol. 14, no. 1, pp. 7-12, viewed 3 May. 2024, https://doi.org/10.26650/experimed.1378000


Harvard: Author-Date Style

Terzi, E. and Öz Bedir, B.E. (2024) ‘A Clinical Sulfonamide Derivative Inhibits B-Raf Protein in Colorectal Cancer and Melanoma Cells. Is It a New Target for Cancer?’, Experimed, 14(1), pp. 7-12. https://doi.org/10.26650/experimed.1378000 (3 May. 2024).


MLA

Terzi, Emine, and Beyza Ecem Öz Bedir. “A Clinical Sulfonamide Derivative Inhibits B-Raf Protein in Colorectal Cancer and Melanoma Cells. Is It a New Target for Cancer?.” Experimed, vol. 14, no. 1, 2024, pp. 7-12. [Database Container], https://doi.org/10.26650/experimed.1378000


Vancouver

Terzi E, Öz Bedir BE. A Clinical Sulfonamide Derivative Inhibits B-Raf Protein in Colorectal Cancer and Melanoma Cells. Is It a New Target for Cancer?. Experimed [Internet]. 3 May. 2024 [cited 3 May. 2024];14(1):7-12. Available from: https://doi.org/10.26650/experimed.1378000 doi: 10.26650/experimed.1378000


ISNAD

Terzi, Emine - Öz Bedir, BeyzaEcem. “A Clinical Sulfonamide Derivative Inhibits B-Raf Protein in Colorectal Cancer and Melanoma Cells. Is It a New Target for Cancer?”. Experimed 14/1 (May. 2024): 7-12. https://doi.org/10.26650/experimed.1378000



TIMELINE


Submitted18.10.2023
Accepted17.02.2024
Published Online25.03.2024

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.